0.6499USD-3.03%Mkt Cap: 9.22M USDP/E: —Last update: 2026-06-01
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap9.22M USD
Enterprise Value6.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-3.85M USD
Revenue/Share—
Last Price0.6499 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.63
EV/Revenue—
P/S—
P/B-2.40
EPS (TTM)-0.33
EPS (Forward)—
52W Range
0.61000% of range9.820
52W High9.820 USD
52W Low0.6100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE195.85%
ROA-798.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.94M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-5.70%
Net Debt1.42M USD
Net Debt/EBITDA-0.38
Balance Sheet
Debt/Equity-0.85
Current Ratio0.13
Quick Ratio0.10
Book Value/Sh-0.2810 USD
Cash/Share0.0340 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.14.02M
Float2.83M
Insiders59.51%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Float5.91%
Short % Out.1.04%
Shares Short75.71K
Technical
SMA 502.725 (-76.2%)
SMA 2002.725 (-76.2%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)3.71M
Avg Vol (10d)4.40M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—